Glafenine

This classification denotes an analgesic agent with the molecular formula C19H17ClN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 46HL4I09AH, chemically known as 2,3-dihydroxypropyl n-(7-chloro-4-quinolyl) anthranilate but generally known as glafenine, which bears US NIH Compound Identifier 3474. European Medicines Agency schedules Glafenine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07909MIG. The term GLAFENINE is an International Non-Proprietary Name. World Health Organization schedules glafenine in its Anatomical Therapeutic Chemical (ATC) Classification. GLAFENINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule glafenine under HS 29334990 and SITC 51575. As of Q4 2014, GLAFENINE remains the US FDA Preferred Term for this commodity. Glafenine bears US NLM identifiers UMLS ID C0017592 and NCI Concept Code C72119. SMILES: CLC1CC2NCCC(NC3C(C(=O)OCC(O)CO)CCCC3)C2CC1.